cancer therapy using alpha-emitters

2015 Fiscal Year Final Research Report

• Project/Area Number: 26670568
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Radiation science
• Research Institution: Kyoto College of Medical Science
• Principal Investigator: ENDO KEIGO 京都医療科学大学, 公私立大学の部局等, その他 (10115800)
• Co-Investigator(Kenkyū-buntansha): HOSONO MAKOTO 近畿大学, 公私立大学の部局等, 教授 (00281303)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: がん治療 / アルファ線 / 抗体 / ベータ線 / RI内用療法 / 放射線管理 / アスタチン211

Outline of Final Research Achievements

Radium-223 has been approved to use clinically for the first time as alpha-emitting radiopharmaceuticals in Japan. Radium-223 is not appropriate for the labeling other tumor seeking substances. Astatin-211, another promising alpha-emitter, has similar characteristics with iodine. In the present study, we found an efficient production method, that is the use of mixture of ethanol and 0.1 NaOH, for the recovery of astatin-211. Half life of astatin-223 is 7 hours, supposed to be too short for whole IgG, and we confirmed rapid distribution and high tumor uptake of iodine-125 labeled Fab fragment as expected. For the comparison between alpha and beta emitting radiopharmaceuticals, yttrium-90, widely used beta-emitter,was labeled with anti-CD 20 antibody and animal study was performes. Tumor suppressive effect was performed by yttrium-90 labeled ones, and this tumor-antibody model will be used for the basic studies of astatin-211 labeled antibody.

Free Research Field

医歯薬学